Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Surgeries

jianxing He, President

wenhua Liang, Director

Chao Lv, Deputy Director

Zitong Wang, Director

Naixin Liang, Deputy Director

Fan Yang

Shaohua Ma, Director

Yi Zhang, Director

Zhiqiang Wang

Xiaojie Pan, Deputy Director

Jian Zhao, Director

Guibin Qiao, Director

Jianxing He, President

Jianjun Lu, Director

Lin Yang, Deputy Director

Jie Chen, Deputy Director

Lei Xian, Director

Fanyi Kong

Junfeng Liu, Director

Mingfei Geng, Director

Li Wei, Director

Yongde Liao

Chunfang Zhang, Director

Liang Chen, Director

Xiaoqiang Liu, Deputy Director

Haitao Ma, Director

Bentong Yu, Director

Dongliang Yu, Director

Wei Liu, Director

Hua Xin, Director

Changhong Liu

Suning Zhang, Director

Shun Xu, Director

Zhiyong Su, Director

Zhanlin Guo, Director

Hui Tian

Baijiang Zhang, Director

Zeshu Li, Director

Hecheng Li, Director

Xiaoqing Zhao

Songtao Xu, Deputy Director

Hongguang Zhang

Lunxu Liu, Vice President

Tianyang Dai

Xun Zhang

Jun Chen, Director

Zhengfu He

Jian Hu, Director

Ying Chai, Director

Qixun Chen, Director

Weiyu Shen, Director

Guangmao Yu

Baofu Chen

This study is a prospective, national, multi-center, non-interventional study. The main purpose is to explore the initial adjuvant treatment pattern after radical resection for early-stage NSCLC patients with EGFR Mutation-Positive in the real world. The secondary purpose was to observe the postoperative follow-up treatment pattern and its subgroups (based on different EGFR mutation status and different clinical stages).

About 2,000 eNSCLC patients who received radical resection from about 50 research centers across the country will be included in this study, and will be followed up to 2 years after enrollment according to the actual clinical situation. The analysis method of this study is mainly based on descriptive statistics. The information about the human genetic resources of the subjects to be collected includes: demography, physical examination, WHO fitness status, medical history, smoking history, disease characteristics, surgical information, initial and follow-up adjuvant treatment pattern, laboratory tests, survival status, and adverse events related to gefitinib/osimertinib, serious adverse events/non-severe ADR, measures taken for adverse events, outcome of adverse events.

A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

A Prospective, National, Multi-center, Non-intervention Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

Descriptive summary statistics ( total number of cases, number of missing cases, frequency, and percentage of each category) were used to describe the distribution of participants with initial adjuvant treatment patterns, including chemical, targeted, combined, or other therapy.

Set subgroup analysis for different initial adjuvant treatment pattern, including different clinical stages (according to phase I/ Phase II/ stage III) and different EGFR mutation status (19del or 21 L858R);

Calculate the time from the start date to the end of initial adjuvant treatment. The total number of cases, number of missing cases, mean, standard deviation, median, 25th and 75th percentiles, minimum and maximum were used for statistical description.

Calculate the interval of operation to the adjuvant therapy with EGFR-TKI, which is classified into single-drug therapy and combined therapy. The total number of cases, number of missing cases, mean, standard deviation, median, 25th and 75th percentiles, minimum and maximum were used for statistical description.

The patients with chemotherapy were mainly calculated, divided into chemotherapy and targeted combination chemotherapy. The total number of chemotherapy cycles, the number of missing cases, the mean, standard deviation, the median, the 25th and 75th percentiles, the minimum and the maximum were statistically described

Descriptive summary statistics ( total number of cases, number of missing cases, frequency, and percentage of each category) were used to describe the distribution of participants with follow-up treatment patterns after advanced events evaluated by an investigator, including chemical, targeted, combined, or other therapy.

Set subgroup analysis for different follow-up treatment pattern including different clinical stages (according to phase I/ Phase II/ stage III) and different EGFR mutation status (19del or 21 L858R);

Calculate the time from the start date to the end of follow-up treatment. The results are shown in months, to one decimal place. The total number of cases, number of missing cases, mean, standard deviation, median, 25th and 75th percentiles, minimum and maximum were used for statistical description.

Calculate the interval of operation to the follow-up treatment with EGFR-TKI, which is classified into single-drug therapy and combined therapy. The results are shown in months, to one decimal place. The total number of cases, number of missing cases, mean, standard deviation, median, 25th and 75th percentiles, minimum and maximum were used for statistical description.

The patients with chemotherapy of follow-up treatment were mainly calculated, divided into chemotherapy and targeted combination chemotherapy. The total number of chemotherapy cycles, the number of missing cases, the mean, standard deviation, the median, the 25th and 75th percentiles, the minimum and the maximum were statistically described

The First Affiliated Hospital of Guangzhou Medical University

Clinical Professor

NSCLC patients,including stage I to stage IV.

Without intervention,this study is just an observational study.

without intervention type

dong xiaorong, Dr

Relationship between human microbiota and epidemiology of lung cancer

In this study,We aim to find some kinds of human microbiota , which were associated with development of non-small cell lung cancer.

We intend to collect the following samples：

1. Blood samples
2. Stool samples
3. Sputum samples
4. Tumor tissue samples

The Role of Microbiota on the Development of Lung Cancer

Find some human microbes that are associated with the development of lung cancer, we can detect these human microbiological content as a biomarker of lung cancer.

Xiaorong Dong

Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China	NCT04830826	NSCLC, Stage I NSCLC, Stage II NSCLC, Stage II...	Surgeries	-	The First Affiliated Hospital of Guangzhou Medical University
The Role of Microbiota on the Development of Lung Cancer	NCT03454685	NSCLC, Stage I NSCLC, Stage II NSCLC, Stage II... NSCLC Stage IV Healthy Subject...	without interve...	18 Years - 70 Years	Wuhan Union Hospital, China

Spots Global Cancer Trial Database for nsclc, stage ii